Bridgebio
Business Services · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
3160 Porter Dr Ste 250, Palo Alto, Calif...Phone Number
(650) 391-9740Website
www.bridgebio.comRevenue
$580 MillionStock Symbol
BBIOIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
7
1
2
2
2
1
About Bridgebio
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.Explore more
Bridgebio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bridgebio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Bridgebio has new funding data
Check out if Bridgebio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Bridgebio
Earning: See what the market has to say on Bridgebio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Bridgebio launches new products
Check if Bridgebio has recently received funding, and reach out quickly before it becomes old news!
Click to see if Bridgebio had a recent Job posting/layoffs
Bridgebio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Bridgebio
Find 3 more new buyers
Compare Similar Companies to Bridgebio
Compare insights from companies similar to Bridgebio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Bridgebio financials insights
Gather financial insights about Bridgebio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series C
$135M
2019
Other Financing Round
$299.2M
2020
Debt
$475M
2021
Debt
$750M
2025
Other Financing Round
$300M
2026
Stock/Share Issuance
$1B
Bridgebio Tech Stack
A closer look at the technologies used by Bridgebio
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Bridgebio News & Media
BridgeBio stock jumps after rival heart drug fails key trial
A rival drug failure can sometimes move a biotech stock almost as much as a company’s own clinical data. That is what happened to BridgeBio on July 9. BridgeBio (BBIO) shares jumped after AstraZeneca and Ionis said Wainua failed to meet the main goal in a late-stage trial for transthyretin-mediated ...Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P<0.05), with no kidney-related adverse events observed in these post-hoc analysesBridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s 30-day VWAP)BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS mean +0.37 SD; p<0.0001), the first and only statistically significant placebo-controlled arm span result reported for an achondroplasia trial at 52 weeks
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bridgebio
Sign Up For FreeTo access detailed company insights
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial... Read More
